Iproteos SL

Obtención de fármacos innovadores y su introducción en el mercado para crear un impacto positivo en la Sociedad.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Barcelona, Spain
  • Currency EUR
  • Founded June 2011
  • Employees 7
  • Website iproteos.com

Company Summary

Iproteos mediante su tecnología IPRO desarrolla fármacos capaces de actuar en casos en los que los tratamientos tradicionales no consiguen tener éxito. IPRO se aplica a proyectos de desarrollo interno y se comercializa como plataforma de servicios para la industria farmacéutica. Contamos con proyectos para el tratamiento de de la esquizofrenia, la epilepsia y cancer pediátrico.

Team

  • Directora General

    Co-founder & CEO. Researcher and manager, 15 years of track
    record. Inventor of 4 patents. Published 40 papers at international peer-reviewed journals.
    ESADE Executive MBA 2012. Worked with many international teams such as CNRS (France),
    Nencki Institute (Poland), UCL (UK). International Education at HEC (France) Weatherhead
    School of Management (USA). Learned entrepreneurship at Judge Business School (UK).

  • Presidente del Comité Científico Asesor

    Prof. Ernest Giralt. Co-founder & Chairman of Scientific Advisory Board. Head of the Chemistry at IRB Barcelona. Internationally Renowned Expert and KOL in Chemistry. Published > 250 papers. Inventor of 10 patents. Visiting Professor, University of California San Diego (USA), Research Associate, Scripps Research Institute, San Diego (USA). Novartis Chemistry Lecturer. Member of advisory boards for pharma and biotech companies.

  • Director Científico

    Dr. Roger Prades. Chief Scientific Officer. Degree in Chemistry and PhD in Chemistry from the University of Barcelona. Executive EOI Master in Innovation 2012. Researcher, 10 years track record in drug discovery. Inventor of 3 patents. Published 9 papers at international peer-reviewed journals. Researcher at Yale University (USA).

  • Directora Desarrollo de Negocio

    Dr. Laura Mendieta. Business Developer Manager. PhD in Biotechnology from the University of Barcelona. Postgraduate on Innovation Management at University of Barcelona 2014.
    Executive EOI Master in Innovation 2015.
    Researcher at Glasgow Biomedical Research Centre (UK), Harvard Medical School (USA) & “Universidade Federal de Santa Maria” (Brazil).

  • Director Química Computacional

    Dr. Jesus Seco. Head of Computational Chemistry. Degree in Chemistry and PhD in Pharmacy at UB (Spain), where he focused on rational computer-based drug design. Researcher at University of Oklahoma (USA). He has participated in many academia-industrial partnerships: Uriach, Sanofi, Noscira, Oryzon. Executive EOI Master in Innovation 2013.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free